CMS's 2027 ratings put 37% of Medicare Advantage drug contracts at four stars or more
The share of Medicare Advantage drug contracts with four or more stars fell to about 37% from 44%, and five-star contracts fell to 15 from 22. But weighted by enrollment, about 71% of members are in four-star-plus contracts.

Fewer Medicare Advantage contracts earned top marks this year, but a larger share of members are enrolled in the ones that did.
About 37% of Medicare Advantage prescription drug contracts, 188 in all, earned an overall rating of four stars or higher in the 2027 Star Ratings that the Centers for Medicare & Medicaid Services published Oct. 8, according to the agency's fact sheet. That compares with about 44% of rated contracts for 2026, based on CMS's year-over-year table.
Why it matters: CMS said the ratings will affect insurers' 2028 Medicare Advantage quality bonus payments, and they appear on Medicare Plan Finder for open enrollment, which runs Oct. 15 through Dec. 7. Measured by members rather than contracts, the count moved the other way: about 71% of MA-PD enrollees are in contracts rated four stars or more for 2027, up from about 67% for 2026, according to CMS's table.
Fewer contracts at the top
CMS rated 508 MA-PD contracts for 2027, down from 516. Fifteen earned five stars, compared with 22 a year earlier, and eight of this year's five-star contracts also held that rating for 2026. The five-star count has swung widely in recent years: 38 contracts reached it for 2024 and nine for 2025, the table shows. The number of contracts at 4.5 stars fell to 65 from 89.
The enrollment-weighted average overall rating for MA-PDs was 3.99, compared with 4.01 for 2026 and 3.95 for 2025. Four contracts will carry Plan Finder's low-performing icon for consistently low ratings, the same number as last year.
Standalone Part D plans posted a larger gain by enrollment. About 27% of prescription drug plan contracts, or 11, earned four stars or more, and those contracts cover about 22% of PDP enrollees, up from 2% in 2026, according to the fact sheet. No standalone PDP earned five stars for 2027.
CMS said nonprofit organizations earn higher ratings more often than for-profit ones: about 44% of nonprofit MA-PD contracts earned four or more stars, versus 34% of for-profit contracts.
Methodology changes, now and ahead
CMS rates MA-PD contracts on as many as 43 measures and sets thresholds, known as cut points, that decide whether performance on each one earns one to five stars.
The 2027 ratings add two measures: concurrent use of opioids and benzodiazepines, and polypharmacy use of multiple anticholinergic medications in older adults. A respecified colorectal cancer screening measure replaced the legacy version, and a functional status assessment measure returned after specification changes. CMS tripled the weight of two measures on improving or maintaining physical and mental health, to three from one. Two Part C measures, pain assessment for older adults and medication reconciliation after discharge, were retired.
CMS also said it began using Part C reporting data to check whether appeals data from the independent review entity were complete, and applied scaled reductions where it found data integrity problems.
The agency noted that cut points are reset every year based on plan performance and that year-over-year changes in ratings are normal and vary by measure.
More changes are already scheduled. A Part D measure on completion of comprehensive medication reviews, moved to CMS's display page for the 2025 and 2026 measurement years, returns as a new measure starting with the 2029 Star Ratings, CMS said.



